Comparative efficacy and safety of PD-1/PD-L1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials
Cancer Cell International,
Abstract Background Triple-Negative Breast Cancer (TNBC) is a lethal subtype of breast cancer with limited treatment options.